Clinical outcome and prognostic factors of patients with early-stage epithelial ovarian cancer

 Blogger's Note: see abstract for detailed stats - removed below for ease of reading

abstract

Some subsets of early stage ovarian cancer patients experience more recurrences than others. Studies on prognostics factors gave conflicting results.

We investigated consecutive 221 patients with stage I/II ovarian cancer at our institution from 1999 to 2010. Univariate and multivariate analysis of progression free survival (PFS) and overall survival (OS) were performed. After a median follow-up of 79 months, the 5-year/10-year PFS and 5-year/10-year OS were 78% /76% and 90% /87% respectively. Multivariate analysis revealed that stage as the most prominent independent prognostic factor in terms of PFS (stage I vs stage IIA vs stage IIB, and OS (stage I vs stage II,. Peritoneal biopsy reduced the risk of recurrence by 29%. Ascites (HR = 2.8 and not the first-line chemotherapy (HR = 2.6) contributed to decreased OS. Overall, early-stage ovarian cancer had a favorable outcome, stage was the most powerful prognostic factor. (HR=hazard ratio)